— Know what they know.
Not Investment Advice

IPIX OTC

Innovation Pharmaceuticals Inc.
1W: +0.0% 1M: +19900.0% 3M: -33.3% YTD: -80.0% 1Y: -93.3% 3Y: -98.0% 5Y: -99.9%
$0.00
-0.00 (-80.00%)
 
OTC · Healthcare · Biotechnology · Tech Score Neutral · Power 49 · $103669 mcap · 514M float · 0.043% daily turnover · Short 32% of daily vol

Balance Sheet Trends

Total Assets
$8M -27.6% ▼
5Y CAGR: +2.8%
Total Liabilities
$5M -3.0% ▼
5Y CAGR: -8.8%
Shareholders Equity
$2M -56.9% ▼
Cash & Investments
$2M -60.1% ▼
5Y CAGR: -8.9%
Total Debt
$725K -43.7% ▼
5Y CAGR: -18.5%
Net Debt
-$1M +50.4% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2019FY2020FY2021FY2022FY2023
— Assets —
Cash$579K$6M$10M$4M$2M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$579K$6M$10M$4M$2M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$46K$0$0$0$116K
Total Current Assets$625K$6M$11M$4M$2M
Property, Plant & Equip.$1K$0$0$0$0
Goodwill & Intangibles$3M$3M$3M$2M$2M
Long-Term Investments$0$0$0$4M$4M
Other Non-Current Assets$78K$78K$856K$137K$78K
Total Non-Current Assets$3M$3M$4M$6M$6M
Total Assets$4M$9M$14M$10M$8M
— Liabilities —
Accounts Payable$641K$557K$1M$1M$1M
Short-Term Debt$2M$2M$1M$250K$213K
Deferred Revenue$0$0$207K$0$0
Other Current Liabilities$1M$2M$1M$2M$1M
Total Current Liabilities$7M$7M$7M$5M$5M
Long-Term Debt$879K$0$0$786K$457K
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$879K$417K$252K$841K$457K
Total Liabilities$8M$8M$7M$6M$5M
— Equity —
Common Stock$21K$33K$44K$51K$52K
Retained Earnings-$95M-$101M-$115M-$122M-$125M
Accumulated OCI-$879K-$13K-$15K$0-$5K
Total Stockholders Equity-$4M$1M$8M$5M$2M
Total Liabilities & Equity$4M$9M$14M$10M$8M
— Key Metrics —
Total Debt$2M$2M$2M$1M$725K
Net Debt$1M-$4M-$8M-$3M-$1M
Total Investments$0$0$0$4M$4M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms